September 8, 2017

ALEXANDRIA, Va. – The American Society of Clinical Oncology, Inc. (ASCO®) has announced that the first three practices in Spain have received Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program™, LLC (QCP). The accreditations were given today at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.

August 22, 2017

A new population-based study shows that palliative care substantially decreased healthcare utilization among Medicare beneficiaries with advanced cancer, resulting in less intensive care being delivered at the end of life. This included lower rates of hospitalization, fewer invasive procedures, and reduced chemotherapy administration at the end of life, along with higher rates of hospice enrollment and stays. This study was published today in the Journal of Oncology Practice (JOP).

July 31, 2017

ALEXANDRIA, Va. - An update of the American Society of Clinical Oncology (ASCO) clinical practice guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued today, provides new evidence-based information on the appropriate use of olanzapine, NK1 receptor antagonists and dexamethasone.

July 19, 2017

The American Society of Clinical Oncology (ASCO) today issued a position statement aimed at contributing to the national dialogue on rising cancer drug prices. The statement, which asserts that any solutions must also preserve patients' access to care and foster innovation, analyzes a wide array of options and recommends that a panel of stakeholders be established to determine which proposals will be effective and develop a uniform approach for assessing the value of drugs.  

July 10, 2017

ALEXANDRIA, Va. - New recommendations on the use of the MammaPrint genomic test issued today will help guide decisions on adjuvant systemic therapy for women with early breast cancer.  The recommendations update the American Society of Clinical Oncology (ASCO) 2016 clinical practice guideline on the use of biomarkers in these patients.

June 12, 2017

The American Society of Clinical Oncology (ASCO) congratulates Dr. Norman "Ned" Sharpless on his appointment as director of the National Cancer Institute (NCI). ASCO is encouraged that NCI will have at its helm an accomplished researcher with experience leading a wide range of clinical and translational research endeavors focused on bringing new insights into cancer prevention and treatment.

June 8, 2017

IRVING, Texas– Caris Life Sciences®, a leading innovator in molecular science, and the American Society of Clinical Oncology, Inc. (ASCO®), today announced that Caris is one of the first laboratories to have a test report optimized for ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) Study. The TAPUR Study is evaluating efficacy of treatments based on patients’ tumor genetic profiles. This designation indicates that the company’s proprietary Caris Molecular Intelligence® comprehensive genomic profiling plus (CGP+) tumor profiling platform report is optimized to molecularly identify and report genomic alterations specifically for the TAPUR Study.

June 8, 2017

The American Society of Clinical Oncology (ASCO) congratulates Francis S. Collins, MD, PhD, on the announcement of his continued service as the Director of the National Institutes of Health (NIH). A renowned researcher and skilled administrator, Dr. Collins appreciates the critical role that federal research plays in advancing our understanding of how to prevent, diagnose, and treat cancer and other life-threatening diseases, and has worked tirelessly to ensure that the United States remains at the forefront of biomedical innovation.

June 5, 2017

CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy  ̶  chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. 

June 3, 2017

CHICAGO  – The American Society of Clinical Oncology’s (ASCO®) Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility.

May 24, 2017

ASCO strongly opposes the Administration’s proposed cuts to federal agencies that support biomedical research and Medicaid for Fiscal Year 2018, including a 21 percent proposed funding cut for the National Institutes of Health (NIH), a 20 percent proposed funding cut for the National Cancer Institute (NCI), and reducing Medicaid funding by more than $600 billion.  Such extreme reductions to programs that are critical to research will fundamentally damage our nation’s progress in treating patients and will irreversibly harm our nation’s already fragile biomedical research infrastructure.

May 15, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Rubinstein will oversee the team working to securely process and analyze the CancerLinQ® platform's patient data from millions of electronic health records to give personalized insights than can improve the quality of care for patients with cancer.

May 4, 2017

ASCO applauds members of the House and Senate for their vote this week to provide a $2 billion increase in funding to the National Institutes of Health (NIH). This marks the first time in more than a dozen years that Congress has provided the NIH with a back-to-back funding increase.

May 2, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Santa Clara Valley Medical Center (SCVMC) in San Jose, Calif. has signed an agreement to participate in the CancerLinQ® platform. 

May 1, 2017

ASCO applauds Congress for its leadership in providing an additional $2 billion in funding for the National Institutes of Health (NIH). This increase reaffirms the United States' longstanding, bipartisan commitment to scientific research, and will reinvigorate the scientific community as it continues to rebuild after a decade of flat funding. It also offers hope to millions of Americans and their families who face a cancer diagnosis every year. 

Pages